Sigma Planning Corp lessened its stake in shares of EXACT Sciences Co. (NASDAQ:EXAS) by 18.1% in the fourth quarter, Holdings Channel reports. The institutional investor owned 5,122 shares of the medical research company’s stock after selling 1,134 shares during the quarter. Sigma Planning Corp’s holdings in EXACT Sciences were worth $269,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Chicago Equity Partners LLC acquired a new stake in shares of EXACT Sciences during the 3rd quarter worth about $2,312,000. Bank of Nova Scotia acquired a new stake in shares of EXACT Sciences during the 2nd quarter worth about $1,482,000. Stifel Financial Corp lifted its stake in shares of EXACT Sciences by 16.5% during the 2nd quarter. Stifel Financial Corp now owns 25,023 shares of the medical research company’s stock worth $888,000 after buying an additional 3,548 shares during the last quarter. Sit Investment Associates Inc. lifted its stake in shares of EXACT Sciences by 168.2% during the 3rd quarter. Sit Investment Associates Inc. now owns 29,900 shares of the medical research company’s stock worth $1,409,000 after buying an additional 18,750 shares during the last quarter. Finally, Columbus Circle Investors lifted its stake in shares of EXACT Sciences by 5.5% during the 3rd quarter. Columbus Circle Investors now owns 133,398 shares of the medical research company’s stock worth $6,286,000 after buying an additional 6,965 shares during the last quarter. Institutional investors own 83.12% of the company’s stock.
EXACT Sciences Co. (EXAS) opened at $48.86 on Friday. EXACT Sciences Co. has a 1 year low of $19.54 and a 1 year high of $63.60. The company has a quick ratio of 9.98, a current ratio of 10.34 and a debt-to-equity ratio of 0.01.
In other EXACT Sciences news, insider Kevin T. Conroy sold 134,057 shares of the firm’s stock in a transaction dated Tuesday, November 21st. The shares were sold at an average price of $59.50, for a total value of $7,976,391.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Kevin T. Conroy sold 101,488 shares of the firm’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $45.72, for a total transaction of $4,640,031.36. Following the completion of the transaction, the insider now directly owns 931,540 shares in the company, valued at $42,590,008.80. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 764,182 shares of company stock worth $40,574,047. 4.00% of the stock is owned by insiders.
A number of analysts have recently issued reports on the stock. William Blair restated a “buy” rating on shares of EXACT Sciences in a research note on Wednesday, January 10th. Robert W. Baird raised their target price on shares of EXACT Sciences from $49.00 to $56.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 31st. Jefferies Group raised their target price on shares of EXACT Sciences to $60.00 and gave the stock a “buy” rating in a research note on Tuesday, October 31st. Benchmark restated a “buy” rating and set a $60.00 target price (up previously from $50.00) on shares of EXACT Sciences in a research note on Tuesday, October 31st. Finally, Leerink Swann set a $67.00 target price on shares of EXACT Sciences and gave the stock a “buy” rating in a research note on Friday, February 9th. Eight equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $52.84.
ILLEGAL ACTIVITY NOTICE: This report was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another publication, it was copied illegally and republished in violation of US and international trademark and copyright law. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/18/sigma-planning-corp-cuts-stake-in-exact-sciences-co-exas.html.
EXACT Sciences Company Profile
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for EXACT Sciences Co. (NASDAQ:EXAS).
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.